Market Overview

FDA Advisory Committee Votes to Recommend Isis' KYNAMRO

Share:
Related SNY
MannKind, Sanofi Reach Agreement on AFREZZA; Sanofi to Purchase $10.2M Worth of Insulin from MannKind
Can Cempra Clear Solithera Hurdle After FDA Reveal?
TiGenix Seeks $53 Million IPO For Promising Stem Cell Treatments (Seeking Alpha)

Genzyme,
a Sanofi company (NYSE: SNY), and Isis Pharmaceuticals
(NASDAQ: ISIS), announced today that the Endocrinologic and
Metabolic Drugs Advisory Committee of the U.S. Food and Drug
Administration (FDA) voted 9 to 6 that Genzyme had provided
sufficient efficacy and safety data to support the marketing of KYNAMRO™
(mipomersen sodium) for the treatment of patients with Homozygous
Familial Hypercholesterolemia (HoFH). Many people with HoFH have
aggressive cardiovascular disease beginning in childhood, and even with
today's therapies remain at significant risk of cardiovascular events.

"We are very encouraged by the support for KYNAMRO at today's Advisory
Committee meeting, which marks a significant and positive step in our

See full press release

Posted-In: News Guidance Contracts Asset Sales Management Global

 

Related Articles (ISIS + SNY)

View Comments and Join the Discussion!